Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2-Breast Cancer

被引：0
|
作者：
Zhou, Yi-Fan
Zhang, Hu-Yun-Long
Jin, Xi
Jiang, Yi-Zhou
Shao, Zhi-Ming
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-15-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-15-09
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [2] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [3] Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy
    Cao, Lu-Qi
    Sun, Haidong
    Xie, Yuhao
    Patel, Harsh
    Bo, Letao
    Lin, Hanli
    Chen, Zhe-Sheng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
    Sarina, Piha-Paul
    Xu, Binghe
    Fan, Ying
    Yuan, Yuan
    Lavasani, Sayeh
    Mortimer, Joanne
    Goel, Sanjay
    Tsimberidou, Apostolia
    Ibrahim, Nuhad
    Abouharb, Sausan
    Barcenas, Carlos
    Lheme, Adaeze
    Karp, Daniel
    Ahnert, Jordi Rodon
    Dumbrava, Ecaterina
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Xu, Ruolan
    Ni, Shumao
    Wu, Frank
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [6] Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2-Breast Cancer
    Bottosso, Michele
    Miglietta, Federica
    Vernaci, Grazia Maria
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Griguolo, Gaia
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2884 - 2894
  • [7] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [8] Impact of molecular subtype and race on HR+, HER2-breast cancer survival
    Reid, Sonya
    Haddad, Diane
    Tezak, Ann
    Weidner, Anne
    Wang, Xuefeng
    Mautz, Brian
    Moore, Jaleesa
    Cadiz, Sydney
    Zhu, Yuwei
    Zheng, Wei
    Mayer, Ingrid A.
    Shu, Xiao-ou
    Pal, Tuya
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 845 - 852
  • [9] Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review
    Pu, Dongqing
    Xu, Debo
    Wu, Yue
    Chen, Hanhan
    Shi, Guangxi
    Feng, Dandan
    Zhang, Mengdi
    Liu, Zhiyong
    Li, Jingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
  • [10] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
    Chang, Jenny C.
    O'Regan, Ruth
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 : S1 - S14
12345